CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Devonian Health Group Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Devonian Health Group Inc
360 rue des Entrepreneurs
Phone: (450) 979-2916p:450 979-2916 MONTMAGNY, QC  G5V 4T1  Canada Ticker: GSDGSD
Business Summary
Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various autoimmune fibroinflammatory diseases with novel therapeutic approaches to targeting unmet medical needs. The Company is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis. It is also involved in the development of cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Its Thykamine is an active lead drug candidate with safety and profiles confirmed in several pre-clinical and clinical studies targeting inflammation. Its cosmeceutical products include R-Spinasome and Purgenesis. The Company’s subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand-name pharmaceutical companies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
10/31/20257/31/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Operating Officer, Chief Scientific Officer Andre P.Boulet 6/23/2024 3/1/2015
President, Chief Executive Officer, Director LucGregoire 65 12/1/2023 3/17/2023
Interim Chief Financial Officer, Controller ColetteLaurin
7 additional Officers and Directors records available in full report.

Business Names
Business Name
GSD
OLE.P

General Information
Number of Employees: 8 (As of 7/31/2025)
Outstanding Shares: 2,765,731 (As of 1/22/2026)
Stock Exchange: CVE


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 3, 2026